# A New Era of Care: What to Expect from Synapticure in 2025 and Beyond

Sandra Abrevaya, CEO and Co-founder of Synapticure, shares the company's plans for the future after announcing the successful completion of their $25M Series A funding.

[Announcing a New Advisory Relationship with The Michael J. Fox Foundation](/content/blog/mjff-michael-j-fox-foundation-advisory-announcement/index.html)

Synapticure announces The Michael J. Fox Foundation as its newest advisor to help improve access to specialty care and to accelerate Parkinson’s research.

[Synapticure Launches an IRB-Approved Study for Presymptomatic Carriers of Pathogenic, ALS-Associated Gene Variants](/content/blog/presymptomatic-irb-approved-study-launch/index.html)

[Synapticure Patient Panel - 01/12/23](/content/blog/synapticure-patient-panel-01-12-23/index.html)

[Improving outcomes and accelerating treatments through data-driven, remote, proactive care](/content/blog/improving-outcomes-and-accelerating-treatments-through-data-driven-remote-proactive-care/index.html)